New Dietary Ingredients: EU versus U.S. Approaches
New Dietary Ingredients: EU versus U.S. Approaches
New dietary ingredients (NDIs) take different approval routes in the EU versus in the United States. On May 7 at Vitafoods Europe, Tennille Marx, ND, senior research associate for natural products consulting firm AIBMR Life Sciences Inc. (Puyallup, WA), will discuss the differences. She’ll also provide insight to non-U.S. companies looking to enter the U.S. dietary ingredient market on how to navigate the U.S. FDA’s regulatory channel for NDIs.
“The authorization process for novel ingredients/foods in the EU has been known to take 35 months on average-and sometimes up to 60 months-whereas the U.S. FDA typically responds in 180 days for GRAS ingredients (novel ingredients) and in 75 days for new dietary ingredients intended for supplements-a major benefit of the U.S. market,” Marx says.
Marx will also focus in on the differences between FDA’s GRAS and NDI regulatory routes, as well as other factors that could dictate the direction of a company’s strategy in the United States, including the FDA’s recently released beverages-versus-supplements draft guidance.
<<Previous Next>>
Balchem’s Newest Launch Optifolin+® Brings Innovation to the Folate Market
November 15th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin+®, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.